Vaxcyte’s VAX-24 IND Cleared by FDA for Prevention of Invasive Pneumococcal Disease in Infants
Vaxcyte, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s infant Investigational New Drug (IND) application for VAX-24, its lead, 24-valent…
Read More...
Read More...